ApoE expression across the CNS: Who, What, Where, When, and How (much)?

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Apolipoprotein E (APOE) is the leading genetic risk factor for late-onset Alzheimer's disease (AD).
• Fundamental questions persist regarding APOE expression patterns within the central nervous system (CNS).
• Understanding APOE's cell-type specific expression, regional distribution, and regulation across lifespan and disease states is critical.

Purpose of the Study:

• To provide a comprehensive framework detailing the cell types, locations, timing, and quantity of APOE/apoE expression in the CNS.
• To synthesize existing transcriptomic, spatial, biochemical, and genetic data.
• To clarify the role of APOE isoforms (E2, E3, E4) in CNS lipid transport and AD pathogenesis.

Main Methods:

• Analysis of large-scale single-cell RNA sequencing datasets.
• Integration of in vivo and cell-type-specific genetic studies.
• Assessment of transcriptomic, spatial, biochemical, and protein-level data.

Main Results:

• Astrocytes are the predominant baseline expressers of APOE in the CNS.
• Microglia, oligodendrocyte-lineage cells, and vascular-associated cells show context-dependent APOE induction, particularly with aging, injury, and AD pathology.
• APOE protein levels often follow an isoform hierarchy (E2 > E3 > E4), with significant post-transcriptional regulation and model-specific effects.

Conclusions:

• Clarifying the spatiotemporal and cell-specific expression of APOE is essential for understanding its role in CNS health and disease.
• A detailed understanding of apoE expression dynamics will facilitate the development of precise, APOE-targeted therapeutic strategies for Alzheimer's disease.
• Addressing discrepancies in neuronal APOE expression and isoform-dependent regulation is key for future research.